Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)
Technology appraisal
Reference number: TA940
Published:
The company is withdrawing the submission for this appraisal so NICE will not be progressing guidance development at this time. The committee meeting previously scheduled for 16 November will not be going ahead.